Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CER-001 Atherosclerosis Regression ACS Trial; A Phase II Multi-Center, Double-Blind, Placebo-Controlled, Dose-Focusing Trial Of Cer-001 In Subjects With Acute Coronary Syndrome

NCT02484378 is registered in ClinicalTrials.gov with Cerenis Therapeutics, SA as lead sponsor.

NCT NCT02484378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02484378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CER-001 Atherosclerosis Regression ACS Trial; A Phase II Multi-Center, Double-Blind, Placebo-Controlled, Dose-Focusing Trial Of Cer-001 In Subjects With Acute Coronary Syndrome
Lead sponsor
Cerenis Therapeutics, SA
Phase
Phase 2
Overall status
Completed
Start date
August 31, 2015
Completion date
December 31, 2016
Enrollment
301 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndromes